Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
4 clinical trials · Condition
◉ Watch Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
| Record | Firm | Date |
|---|---|---|
| Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL) (NCT03207542) | M.D. Anderson Cancer Center | 2018-07-01 |
| Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) (NCT03207555) | M.D. Anderson Cancer Center | 2018-05-23 |
| Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas (NCT03205891) | M.D. Anderson Cancer Center | 2018-03-01 |
| Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma (NCT03283046) | M.D. Anderson Cancer Center | 2017-10-01 |
Track Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic automatically
Every clearance here is in the API, with alerts when new ones post.